These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 18465652)

  • 1. Risedronate Norwich-Eaton Pharmaceuticals Inc.
    Norman P
    IDrugs; 1998 Nov; 1(7):818-28. PubMed ID: 18465652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. History of risedronate.
    McClung MR; Ebetino FH
    Bone; 2020 Aug; 137():115407. PubMed ID: 32387834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
    Siris ES; Lyles KW; Singer FR; Meunier PJ
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Paget's disease of bone.
    Langston AL; Ralston SH
    Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Paget's disease of bone: a survey of clinical practice in Australia.
    Walsh JP; Attewell R; Stuckey BG; Hooper MJ; Wark JD; Fletcher S; Ferrari V; Eisman JA
    Bone; 2008 Jun; 42(6):1219-25. PubMed ID: 18353737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates in the treatment of disorders of mineral metabolism.
    Singer FR; Minoofar PN
    Adv Endocrinol Metab; 1995; 6():259-88. PubMed ID: 7671099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate use in the treatment of Paget's disease of the bone: analysis of claims in a large database.
    Dolgitser M; Stern L; Katz LM; Doyle JJ; Omar M; Seton M; Kahler KH
    Manag Care Interface; 2007 Feb; 20(2):33-40. PubMed ID: 17405580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risedronate, a novel pyridinyl bisphosphonate for the treatment of osteoporosis and Paget's disease of bone.
    Licata AA
    Expert Opin Investig Drugs; 1999 Jul; 8(7):1093-102. PubMed ID: 15992109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risedronate: clinical usage.
    Chapurlat RD; Delmas PD
    Int J Clin Pract; 2001 May; 55(4):275-8. PubMed ID: 11406915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological therapy of Paget's and other metabolic bone diseases.
    Hosking D
    Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone.
    Reginster JY; Treves R; Renier JC; Amor B; Sany J; Ethgen D; Picot C; Franchimont P
    J Bone Miner Res; 1994 May; 9(5):615-9. PubMed ID: 8053389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.
    Hodsman A; Adachi J; Olszynski W
    CMAJ; 1996 Oct; 155(7):945-8. PubMed ID: 8837544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
    Eastell R; Barton I; Hannon RA; Chines A; Garnero P; Delmas PD
    J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report of implant placement in a patient with Paget's disease on bisphosphonate therapy.
    Pirih FQ; Zablotsky M; Cordell K; McCauley LK
    J Mich Dent Assoc; 2009 May; 91(5):38-43. PubMed ID: 19537656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates: from bench to bedside.
    Russell RG
    Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.
    Siris ES; Chines AA; Altman RD; Brown JP; Johnston CC; Lang R; McClung MR; Mallette LE; Miller PD; Ryan WG; Singer FR; Tucci JR; Eusebio RA; Bekker PJ
    J Bone Miner Res; 1998 Jun; 13(6):1032-8. PubMed ID: 9626635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.